Aktienanalyse zu Ocular Therapeutix Inc (OCUL)OCULOcular Therapeutix Inc

Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ocular Therapeutix Inc is not a good buy right now due to significant recent declines and competitive pressures. The current price is $6.87, down 41.88% year-to-date, and the RSI is at a low 26.456, indicating oversold conditions. While analysts have set price targets as high as $30, the stock has faced a 22% drop recently due to competitive pressures, which poses a risk to recovery. Additionally, insider selling has increased by 186.05%, suggesting a lack of confidence from company insiders, which is a concerning signal for potential investors.

7 analysts cover OCUL: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 23.43.